Non-small cell lung cancer, RET-positive
Jump to navigation
Jump to search
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBSUniversity of MinnesotaMinneapolis, MN AmitKulkarniMD
|
 |
Travis Osterman, DO, MSVanderbilt UniversityNashville, TNTravisOstermanLinkedIn
|
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
Metastatic disease
1 regimens on this page 7 variants on this page
|
Selpercatinib monotherpay
Regimen
| FDA-recommended dose |
|---|
| Study | Years of enrollment | Evidence |
|---|---|---|
| Drilon et al. 2019
LIBRETTO-001 |
Phase I/II |
Biomarker eligibility criteria
- Biomarker: RET fusion positive
Chemotherapy
- Selpercatinib 120 mg (<50 kg) and 160 mg (>50 kg) orally twice daily with or without food
Continued indefinitely
References
- Abstract. Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. link to abstract.